Novel cutaneous eruptions in the setting of PD-1 inhibitor therapy
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Supplemental Figures for "Novel cutaneous eruptions in the setting of PD-1 inhibitor therapy"
应用场景：
创建时间：
2022-11-18
相关数据集
Supplementary Material for: When Uveitis and Hypotony Meets Bilateral Iris Retraction Syndrome: A Rare but Serious Complication of Nivolumab Treatment
Purpose: Iris retraction syndrome (IRS) is a rare clinical condition characterized by a backbowing of the iris appositioned on the lens with complete pupillary block. Immune checkpoint inhibitors (ICI
DataCite Commons2024-06-23 更新60
DataSheet_1_The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis.csv
BackgroundThyroid dysfunction is common for cancer patients receiving PD-1/PD-L1 inhibitor therapies. To clarify the incidence risk of thyroid dysfunction would be important for guiding anti-PD-1 and
NIAID Data Ecosystem40
Immune cells and their inflammatory mediators modify beta cells and cause checkpoint inhibitor-induced diabetes
Checkpoint inhibitors (CPIs) targeting PD-1/PD-L1 and CTLA-4 have revolutionized cancer treatment but can trigger autoimmune complications including CPI-induced diabetes (CPI-DM), which occurs prefere
NIAID Data Ecosystem30
An agonistic anti-CD137 antibody promotes inflammatory signatures in immune cells that disrupt germinal center formation and T cell-dependent antibody responses II
CD137 is a costimulatory receptor expressed on natural killer cells, T cells, and subsets of dendritic cells. An agonistic monoclonal antibody (mAb) against CD137 has been used to reduce tumor burden
NIAID Data Ecosystem40
Inhibition of IL-17A Protects against Thyroid Immune-related Adverse Events while Preserving Checkpoint Inhibitor Anti-tumor Efficacy [RNA-seq (murine)]. Inhibition of IL-17A Protects against Thyroid Immune-related Adverse Events while Preserving Checkpoint Inhibitor Anti-tumor Efficacy [RNA-seq (murine)]
Checkpoint inhibitor (ICI) immunotherapy leverages the body’s own immune system to attack cancer cells but leads to unwanted autoimmune side effects in up to 60% of patients. Such immune related adver
NIAID Data Ecosystem40
